Checkpoint Therapeutics (CKPT) Given Media Sentiment Score of 0.13

News articles about Checkpoint Therapeutics (NASDAQ:CKPT) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 48.84968504939 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Checkpoint Therapeutics stock traded up $0.05 during mid-day trading on Monday, reaching $3.88. 131,090 shares of the stock traded hands, compared to its average volume of 147,212. The stock has a market cap of $122.97 million, a PE ratio of -3.88 and a beta of -0.07. Checkpoint Therapeutics has a 12-month low of $2.22 and a 12-month high of $10.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.37 million. Checkpoint Therapeutics had a negative return on equity of 126.68% and a negative net margin of 2,367.51%. equities research analysts anticipate that Checkpoint Therapeutics will post -1.02 EPS for the current fiscal year.

A number of analysts recently commented on the company. ValuEngine upgraded Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. HC Wainwright set a $11.00 price objective on Checkpoint Therapeutics and gave the company a “buy” rating in a research report on Monday, August 20th. Finally, Zacks Investment Research cut Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 11th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.

See Also: Stock Symbol

Insider Buying and Selling by Quarter for Checkpoint Therapeutics (NASDAQ:CKPT)

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply